Lysogene’s Capital Increase

Dechert LLP and Villey Girard Grolleaud advised Lysogene S.A. on the transaction Lysogene S.A., a pioneering Phase 3 gene therapy platform company targeting central nervous system…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Paolo Bossi

This content is for Standard 1 Year members only.
Login Join Now